A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

• Status: Completed
• Trial end date: 2021-04-09
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of FOY-305 in patients with SARS-CoV-2 infection (COVID-19) in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ono Pharmaceutical Co. Ltd
• Treatments: Camostat

Criteria

Inclusion Criteria:

1. Inpatient or outpatient: Inpatient

2. Positive SARS-CoV-2 test by a method eligible for definitive diagnosis

3. Enrollment in this study within 5 days after onset of symptoms of SARS-CoV-2 infection (COVID-19) (for asymptomatic patients, enrollment in this study within 5 days after collection of the sample that tested positive)

Exclusion Criteria:

1. Receiving oxygen therapy

2. Difficulty in swallowing oral medication

3. History of COVID-19

4. History of vaccination against COVID-19

5. Taking camostat mesilate